Medical News

RSS

Many genetic disorders respond well to specialized gene therapy

When the normal DNA sequence in an individual changes or mutates it can cause disease. The mutation may involve multiple genes and may be caused by environmental factors, or there may be chromosomal defects that are harmful at birth, in infancy or environment at a later stage.

12 Dec 2022

Study provides new insights for the future development of oral insulin pill

WEHI researchers in Melbourne have answered a 100-year-old question in diabetes research: can a molecule different to insulin have the same effect? The findings provide important insights for the future development of an oral insulin pill.

12 Dec 2022

Novel monoclonal antibody therapy shows promising results in patients with moderate to severe atopic dermatitis

Patients with moderate to severe atopic dermatitis who participated in a clinical trial of rocatinlimab - a novel, patient-tailored monoclonal antibody therapy - showed promising results both while taking the drug and up to 20 weeks after the therapy was stopped, Mount Sinai researchers reported in The Lancet.

12 Dec 2022

GOSH delivers world-first base-edited cell therapy for a patient with relapsed T cell leukemia

A patient with relapsed T cell leukemia has been given base-edited T-cells in a world-first use of a base-edited cell therapy, in a 'bench-to-bedside' collaboration between UCL and Great Ormond Street Hospital for Children (GOSH).

12 Dec 2022

Signaling pathway within brain cells regulates sleep

A good night's sleep can work wonders for both mind and body. But what is it that determines how much we need to sleep, and what can cause us to sleep more deeply?

12 Dec 2022

Cambridge scientists develop a comprehensive tool for predicting individual's risk of prostate cancer

Cambridge scientists have created a comprehensive tool for predicting an individual's risk of developing prostate cancer, which they say could help ensure that those men at greatest risk will receive the appropriate testing while reducing unnecessary – and potentially invasive – testing for those at very low risk.

12 Dec 2022

What are the patterns of symptoms and risk factors for Long COVID among SARS-CoV-2 infected individuals?

Researchers explored the indicators of long COVID symptoms.

12 Dec 2022

Three-drug combination highly effective in patients with high-risk forms of chronic lymphocytic leukemia

A three-drug combination that sent chronic lymphocytic leukemia (CLL) into deep remissions in a broad group of patients in a clinical trial is highly effective in patients with high-risk forms of the disease, a new, phase 2 clinical trial led by Dana-Farber Cancer Institute investigators indicates.

12 Dec 2022

Research reveals the assembly dynamics of nucleocapsid protein condensates can be regulated by small molecules with therapeutic potential

Researchers developed a screening platform and identified molecules with anti-CoV activity.

12 Dec 2022

Extra year of chemotherapy lowers the risk of cancer recurrence in children with Ikaros leukemia

Many children with ALL have a good outcome of their disease. After two years of chemotherapy treatment, nine out of ten children are cured. But some children have a more aggressive form of the disease.

12 Dec 2022

Bioengineered soluble ACE2 for brain protection against SARS-CoV-2 infection

Researchers compared the efficiency of bioengineered soluble ACE-2 concerning brain protection during COVID-19.

12 Dec 2022

$Forxiga (dapagliflozin) approved in Great Britain for symptomatic chronic heat failure across the full spectrum of left ventricular ejection fraction$

Forxiga (dapagliflozin) approved in Great Britain for symptomatic chronic heat failure across the full spectrum of left ventricular ejection fraction

AstraZeneca today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a licence extension for dapagliflozin in Great Britain for the treatment of symptomatic chronic heart failure (HF) in patients with HF and a left ventricular ejection fraction (LVEF) >40%, including HF with mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF).

From AstraZeneca 12 Dec 2022

The benefit-risk of the mRNA-1273 COVID-19 vaccine

Researchers modeled the benefit-risk of Moderna’s COVID-19 mRNA-1273 vaccine.

12 Dec 2022

Knowledge and attitudes to mpox among GBMSM in Australia

Researchers presented the results of a cross-sectional survey done in Australia between August and September 2022.

12 Dec 2022

In rural America, deadly costs of opioids outweigh the dollars tagged to address them

Tim Buck knows by heart how many people died from drug overdoses in his North Carolina county last year: 10. The year before it was 12 — an all-time high.

12 Dec 2022

KHN investigation: The system feds rely on to stop repeat health fraud is broken

The federal system meant to stop health care business owners and executives from repeatedly bilking government health programs fails to do so, a KHN investigation has found.

12 Dec 2022

Aging influences the diagnosis and treatment of heart attacks in patients over age 75

For people ages 75 and older, age-related changes in general health and in the heart and blood vessels require consideration and likely modifications in how heart attacks and heart disease are treated, according to a new American Heart Association scientific statement published today in the Association's flagship, peer-reviewed journal Circulation.

12 Dec 2022

Medical News

Many genetic disorders respond well to specialized gene therapy

Study provides new insights for the future development of oral insulin pill

Novel monoclonal antibody therapy shows promising results in patients with moderate to severe atopic dermatitis

GOSH delivers world-first base-edited cell therapy for a patient with relapsed T cell leukemia

Signaling pathway within brain cells regulates sleep

Cambridge scientists develop a comprehensive tool for predicting individual's risk of prostate cancer

What are the patterns of symptoms and risk factors for Long COVID among SARS-CoV-2 infected individuals?

Three-drug combination highly effective in patients with high-risk forms of chronic lymphocytic leukemia

Research reveals the assembly dynamics of nucleocapsid protein condensates can be regulated by small molecules with therapeutic potential

Extra year of chemotherapy lowers the risk of cancer recurrence in children with Ikaros leukemia

Bioengineered soluble ACE2 for brain protection against SARS-CoV-2 infection

Forxiga (dapagliflozin) approved in Great Britain for symptomatic chronic heat failure across the full spectrum of left ventricular ejection fraction

The benefit-risk of the mRNA-1273 COVID-19 vaccine

Knowledge and attitudes to mpox among GBMSM in Australia

In rural America, deadly costs of opioids outweigh the dollars tagged to address them

KHN investigation: The system feds rely on to stop repeat health fraud is broken

Aging influences the diagnosis and treatment of heart attacks in patients over age 75

Study shows emerging Omicron sublineages efficiently evade neutralization independent of immunization history

Multiscale landscaping of droplet wettability and mobility of N95 masks

What is the incidence of viral rebound after treatment with nirmatrelvir-ritonavir and molnupiravir?

How real-time off-gas analysis improves fermentation process control

Advancing Drug Safety Assessment With AI, Predictive Modeling, and Human-Relevant Data

AI-powered analytics and experimental validation

Latest News